Analyst consensus rating
Supernus Pharmaceuticals Analyst Rating: none
SUPN is rated none by 4 analysts with a $61.75 target. As of 2026-08-26.
Direct answer
Supernus Pharmaceuticals's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $61.75.
Forecast evidence checked August 26, 2026.
Get free Supernus Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $45.36
- Average price target
- $61.75
- High price target
- $67.00
- Low price target
- $55.00
- Low target gap
- +21.3%
- Target upside
- +36.1%
- High target gap
- +47.7%
- Target range width
- 26.5%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- August 26, 2026
- Valid through
- September 2, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Supernus Pharmaceuticals?
Supernus Pharmaceuticals has a verified none consensus. The same dataset has an average price target of $61.75.
How far are Supernus Pharmaceuticals's low and high targets from the recorded price?
The low target implies +21.3%, while the high target implies +47.7%.
How many analysts are included in Supernus Pharmaceuticals's consensus?
The verified consensus includes 4 analysts.
How is Supernus Pharmaceuticals's target upside or downside calculated?
The average target of $61.75 is divided by the recorded price of $45.36, then one is subtracted to produce +36.1%. This does not guarantee a future return.
When was Supernus Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-26. The dataset is valid through 2026-09-02.